[HTML] mdpi.com

[HTML][HTML] Radiolabeled somatostatin analogs—a continuously evolving class of radiopharmaceuticals

M Fani, R Mansi, GP Nicolas, D Wild - Cancers, 2022 - mdpi.com
Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology
because these proteins are overexpressed on the cell membranes of different human …
被引用次数：39 相关文章

Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals

M Fani, R Mansi, GP Nicolas, D Wild - Cancers, 2022 - search.proquest.com
Somatostatin receptors (SSTs) are recognized as favorable molecular targets in
neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs), with subtype 2 …

Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.

M Fani, R Mansi, GP Nicolas, D Wild - Cancers, 2022 - europepmc.org
Somatostatin receptors (SSTs) are recognized as favorable molecular targets in
neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs), with subtype 2 …

Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals

M Fani, R Mansi, GP Nicolas, D Wild - Cancers, 2022 - pubmed.ncbi.nlm.nih.gov
Somatostatin receptors (SSTs) are recognized as favorable molecular targets in
neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs), with subtype 2 …

Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals.

M Fani, R Mansi, GP Nicolas, D Wild - Cancers, 2022 - search.ebscohost.com
Abstract Simple Summary: Somatostatin receptors (SSTs) are of particular interest in
oncology because these proteins are overexpressed on the cell membranes of different …
[HTML] nih.gov

[HTML][HTML] Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals

M Fani, R Mansi, GP Nicolas, D Wild - Cancers, 2022 - ncbi.nlm.nih.gov
Somatostatin receptors (SSTs) are recognized as favorable molecular targets in
neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs), with subtype 2 …

Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.

M Fani, R Mansi, GP Nicolas, D Wild - Cancers, 2022 - europepmc.org
Somatostatin receptors (SSTs) are recognized as favorable molecular targets in
neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs), with subtype 2 …